REWIND misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Anneke van der Molen
Page 3 of 8 of this archive, newest first.
Archive — page 3
148 piecesTRIUMPH-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What a low result means when intake has halved
Reduced intake is a plausible mechanism for deficiency. Reduced absorption is not, and the two are conflated in most of the advice.
How much of retatrutide weight loss can any instrument actually attribute?
The instrument determines the answer more than the drug does, and the trade quotes the answer without naming the instrument.
The incidence tables, read line by line
Almost every figure in circulation about tolerability comes from six publications. This is what they say.
How much of cagrilintide weight loss can any instrument actually attribute?
The compartment called lean mass contains water, glycogen, viscera and skin. Only some of it is the tissue anybody is worried about.
SURMOUNT-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why receptor selectivity is the least discussed number in incretin pharmacology
The class is described as though every molecule in it did the same thing. At the receptor, they demonstrably do not.
Non-responders, and the honest state of the evidence about them
The mechanism is well described. The variance is not.
PIONEER 6 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SELECT misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The interventions with trial support, and the much longer list without
The intervention with the clearest evidence is the one nobody frames as an intervention: adjusting the dose.
What a low result means when intake has halved
Micronutrient guidance for this drug class is borrowed almost entirely from post-bariatric surveillance, where the anatomy is different and the deficiency mechanisms are not…
The interventions with trial support, and the much longer list without
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
Coming off: what the pharmacology permits
What a slow reduction could plausibly buy, and what it certainly cannot prevent.
Why your laboratory interval differs from the one in the textbook
A twelve-analyte panel in a perfectly healthy person has roughly even odds of producing at least one flagged result.
What the GLP-1 receptor actually does when orforglipron binds it
The class is described as though every molecule in it did the same thing. At the receptor, they demonstrably do not.